



## **Jazz Pharmaceuticals Announces Closing of Registered Direct Offering**

July 21, 2008

PALO ALTO, Calif., July 21 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that it has completed the previously announced registered direct offering of 3,848,289 units (the "Units"), with each Unit consisting of (i) one share of the Company's common stock, par value \$0.0001 per share ("Common Stock"), and (ii) a warrant to purchase 0.45 of a share of Common Stock, for gross proceeds of approximately \$26.0 million, before deducting placement agents' fees and estimated offering expenses. Lazard Capital Markets LLC served as lead placement agent and Leerink Swann LLC served as co-placement agent for the offering.

The securities described above were offered by Jazz Pharmaceuticals pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission (the "SEC").

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities may be offered only by means of a prospectus. Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the SEC's website at <http://www.sec.gov> or from Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit <http://www.JazzPharmaceuticals.com>.

SOURCE Jazz Pharmaceuticals, Inc.

CONTACT: Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners for Jazz Pharmaceuticals, Inc.; or Matthew Fust, Chief Financial Officer of Jazz Pharmaceuticals, Inc., +1-650-496-2800, [investorinfo@jazzpharmaceuticals.com](mailto:investorinfo@jazzpharmaceuticals.com)  
Web site: <http://www.jazzpharmaceuticals.com>